Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors

This study identifies semicarbazone and thiosemicarbazone analogs, particularly compound 25, as promising noncovalent competitive inhibitors of the SARS-CoV-2 main protease (Mpro) through a combined approach of virtual screening targeting an allosteric site, biochemical validation, and molecular dynamics simulations.

The Gist

The Big Picture: A New Key for a Locking Door

Imagine the SARS-CoV-2 virus (the virus that causes COVID-19) is a burglar trying to break into a house. To get inside and start causing trouble, the burglar needs a master key to unlock a specific door. In the virus, this "door" is a protein called Main Protease (Mpro). Without this protein working, the virus cannot copy itself or spread.

For a while, scientists have been making "locks" (drugs) that jam this door from the inside. However, the virus is sneaky; it keeps changing its shape (mutating), making the old locks stop working. This is why we need new types of locks.

This paper describes how a team of scientists in Brazil found a brand new type of lock that works differently. Instead of jamming the door from the inside, they found a way to jam the door from the outside (an "allosteric" site), or surprisingly, found that their new key actually works best by jamming the door from the inside after all.

---

Step 1: The Digital Treasure Hunt (Virtual Screening)

The scientists didn't just guess; they used a super-fast computer program to look through a digital library of 2,060 different chemical compounds. Think of this like a massive online store with 2,000 different keys.

They were looking for keys that fit into a specific "side pocket" on the virus's door (the allosteric site). They hoped to find a key that would stick there and stop the door from opening.

The Result: Out of 2,000 keys, they picked 41 that looked promising. They then tested these in a real lab.

Step 2: The Lab Test (The "Aha!" Moment)

In the lab, they mixed the virus protein with the chemical keys.

• Most of the keys did nothing.
• One key, called Compound 25 (a type of molecule called a semicarbazone), actually stopped the virus protein from working. It was about 50% effective at a high concentration.

Step 3: The Plot Twist (The Computer Simulation)

Here is where the story gets interesting. The scientists thought Compound 25 was sticking to the "side pocket" (the allosteric site) they had targeted.

So, they ran a high-tech computer simulation (like a movie of the molecule moving) to see exactly what was happening.

• The Surprise: The simulation showed that Compound 25 was unstable in the side pocket. It kept slipping out.
• The Migration: Instead, the molecule slid over to the main door (the active site) and stuck there firmly.

It turns out, the computer predicted it would be a "side-pocket jammer," but the molecule decided to be a "main-door jammer" instead. This is a competitive inhibitor, meaning it fights the virus for the same spot the virus needs to use.

Step 4: Making Better Keys (The Analogs)

Once they found Compound 25 worked, they asked: "Can we make it stronger?"

They looked at 11 similar molecules (cousins of Compound 25). They made two main changes:

1. Changed the shape: They tried removing or changing parts of the molecule. This usually made the drug worse. It turned out the specific shape of the original molecule was crucial.
2. Swapped the material: They changed a specific part of the molecule from an "oxygen" version (semicarbazone) to a "sulfur" version (thiosemicarbazone).

The Winner: The sulfur versions (Compounds 50 and 51) were much stronger! They stopped the virus protein even better than the original.

• Compound 50 was the champion, stopping the virus very effectively.

Step 5: How It Works (The Mechanism)

The scientists wanted to know how these new keys stopped the virus.

• Old Theory: Many similar drugs work by "gluing" themselves to the virus (covalent binding), which is permanent.
• New Discovery: These new drugs work like a magnet. They stick to the virus tightly but can let go (reversible/non-covalent). This is actually good news because it means the drug is less likely to cause permanent damage to human cells, making it safer.

They also checked if these drugs would hurt other parasites (like those causing malaria or sleeping sickness). They found that Compound 50 was very picky—it only attacked the COVID virus and ignored the parasites. This is called selectivity, and it's a sign of a good, safe drug.

Summary: Why This Matters

1. New Strategy: They found a new way to fight the virus, even though the virus is changing (mutating).
2. Better Molecules: They discovered that a specific family of chemicals (thiosemicarbazones) is very good at stopping the virus.
3. Safety: These drugs seem to work by reversible binding, which is generally safer than "gluing" drugs.
4. Future Hope: While these drugs aren't ready to be pills you buy at the store yet (they are still in the early research phase), they are a very promising starting point. They give scientists a new blueprint for building better medicines to fight current and future coronavirus variants.

In short: The scientists used a computer to find a needle in a haystack, realized the needle was actually a different shape than they expected, tweaked it to make it sharper, and found a new tool that could help lock the virus out of our cells.

Technical Summary

1. Problem Statement

Despite the availability of vaccines and antivirals (e.g., nirmatrelvir/Paxlovid), the continued emergence of SARS-CoV-2 variants with mutations in the Main Protease (Mpro) active site poses a significant threat of drug resistance. Mutations at residues such as Glu166, Met165, and His172 have been shown to drastically reduce the efficacy of current covalent inhibitors. There is an urgent need for new therapeutic agents that:

• Target conserved regions or alternative sites to circumvent resistance.
• Offer a different mechanism of action (e.g., non-covalent, reversible inhibition) to avoid cross-resistance with existing covalent drugs.
• Are effective against emerging variants.

2. Methodology

The study employed a multi-stage structure-based drug design (SBDD) and biochemical validation pipeline:

• Target Selection: The researchers focused on allosteric site 1 of SARS-CoV-2 Mpro (a hydrophobic pocket in the C-terminal dimerization domain), distinct from the active site, to potentially avoid resistance mutations found in the catalytic cleft.
• Virtual Screening (VS):
  • Ligand Libraries: Two libraries totaling 2,060 compounds (ENSJ and BraCoLi) were screened.
  • Docking Protocol: The DockThor server was selected after validation via redocking and cross-docking experiments against known allosteric ligands (e.g., ifenprodil, AT-7519). The highest-resolution structure (PDB: 7AQI, 1.70 Å) was used for the screening.
  • Selection Criteria: Compounds were prioritized based on chemical diversity, favorable interactions with key allosteric residues (Ile213, Leu253, Gln256, Val297, Cys300), and exclusion of compounds with excessive polar groups lacking interactions.
• Biochemical Assays:
  • Recombinant SARS-CoV-2 Mpro activity was measured using a fluorogenic substrate cleavage assay (FRET).
  • Initial screening was performed at 100 µM (or max solubility).
  • Hit compounds underwent dose-response analysis to determine IC50 values.
• Molecular Dynamics (MD) Simulations:
  • MD simulations (500 ns) were conducted using GROMACS to assess the stability of the top hit (Compound 25) at the allosteric site and to explore potential binding modes.
  • Clustering analysis was used to identify stable binding conformations.
• Kinetic Analysis:
  • Michaelis-Menten kinetics and Lineweaver-Burk plots were used to determine the inhibition mechanism (competitive vs. non-competitive) and calculate Ki values.
  • Time-dependence assays were performed to distinguish between covalent and non-covalent inhibition.
• Structure-Activity Relationship (SAR):
  • 11 analogs of the lead compound were synthesized and tested to understand the impact of phenyl ring substitutions and the conversion of semicarbazone to thiosemicarbazone scaffolds.

3. Key Contributions

• Discovery of Novel Scaffolds: Identification of semicarbazone and thiosemicarbazone derivatives as potent SARS-CoV-2 Mpro inhibitors.
• Mechanistic Insight: Demonstration that these compounds act as reversible, non-covalent competitive inhibitors, a distinct mechanism from the covalent inhibitors currently in clinical use (e.g., nirmatrelvir).
• Unexpected Binding Mode: The study revealed that while the initial screening targeted an allosteric site, the lead compound (25) dynamically migrated to the active site during simulations, where it formed stable interactions. This was experimentally confirmed as the primary mode of action.
• Selectivity Data: Evidence of selectivity for SARS-CoV-2 Mpro over parasite cysteine proteases (TbrCatL, cruzain, SmCB1) for specific analogs, suggesting a favorable safety profile regarding off-target effects.

4. Key Results

• Virtual Screening & Initial Hits: From 2,060 compounds, 41 were selected for testing. Four showed >50% inhibition at 100 µM.
• Lead Compound (Compound 25):
  • A semicarbazone derivative with an IC50 of 99 ± 0.3 µM.
  • MD simulations showed instability at the allosteric site but stable binding at the active site, forming hydrogen bonds with Ser46 and hydrophobic contacts with Met49 and Met165.
  • Kinetic analysis confirmed competitive inhibition with a Ki of 87.4 µM.
• Optimization (Thiosemicarbazones):
  • Replacing the semicarbazone oxygen with sulfur (thiosemicarbazone) significantly improved potency.
  • Compound 50 (4-methoxyphenyl thiosemicarbazone): IC50 = 61 ± 5 µM, Ki = 18.2 µM.
  • Compound 51 (3,4-dimethoxyphenyl thiosemicarbazone): IC50 = 70 ± 7 µM.
  • Both compounds 50 and 51 were confirmed as non-covalent, competitive inhibitors (no time-dependent inhibition observed).
• SAR Findings:
  • The phenolic hydroxyl group in Compound 25 is critical for activity (methylation or removal abolished activity).
  • Thiosemicarbazones generally outperformed semicarbazones, likely due to increased electrophilicity and favorable interactions, though they retained a non-covalent mechanism in this specific scaffold.
• Selectivity: Compound 50 showed high selectivity for SARS-CoV-2 Mpro, being inactive against the tested parasitic proteases, whereas other analogs showed cross-reactivity.

5. Significance

This study provides a promising new avenue for SARS-CoV-2 therapeutics by identifying reversible, non-covalent competitive inhibitors that target the active site but are derived from a scaffold (thiosemicarbazone) distinct from current clinical drugs.

• Resistance Mitigation: Because these compounds bind reversibly and non-covalently, they may remain effective against variants that have developed resistance to covalent inhibitors (like nirmatrelvir) by altering the active site geometry or nucleophilicity.
• Drug Development Potential: The identification of the thiosemicarbazone scaffold as a viable, non-covalent inhibitor offers a new chemical starting point for medicinal chemistry optimization to improve potency (current IC50s are in the micromolar range) and pharmacokinetic properties.
• Methodological Validation: The study highlights the utility of combining virtual screening (even when targeting allosteric sites) with rigorous MD simulations and biochemical validation to uncover unexpected binding modes (allosteric-to-active site migration).